GH Guardant Health, Inc. Loading... : Bullish and Bearish Analyst Opinions

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
08:30
Jul 19
Choi Chang-gyu Director, NH Investment & Securities 815 Money Talk (815머니톡)
Buy Guardant Health and Natera on biotech rotation.
Retail investors are rotating out of crowded tech positions into biotech and healthcare. Guardant Health (liquid biopsy, early cancer detection) and Natera (genetic testing, recurrence monitoring) are leading liquid-biopsy companies that rank high among retail purchases. This rotation into defensive biotech leaders gives them added demand and supports a positive outlook.
GH 1ST
MED
12:24
May 13
Andy Constan Founder, Damped Spring Advisors
Long GH as part of a diversified basket of stocks the author buys daily for retirement.
GH
HIGH
12:00
Apr 21
Alex Karnal Partner, Andreessen Horowitz ILTB Podcast
Cancer screening companies are growing rapidly.
Companies like Exact Sciences and Guardant Health are advancing colorectal cancer screening with stool-based and blood tests, respectively, making screening more convenient and increasing adoption. Blood tests are inflecting and multi-cancer early detection tests are emerging, which could lead to earlier cancer detection and better outcomes.
GH 1ST
HIGH

About GH Analyst Coverage

Buzzberg tracks GH (Guardant Health, Inc.) across 3 sources. 2 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (67%). 3 total trade ideas tracked. Past 7 days: 1 bullish. Latest voices: Choi Chang-gyu, Andy Constan, Alex Karnal.